Brief: Adaptimmune Announces Overall Response Rate Of 36% In Its Cancers Clinical Trial

Adaptimmune Therapeutics

13/09/2021 13:57

Sept 13 (Reuters) - Adaptimmune Therapeutics PLC  ADAP.O :
    * ADAPTIMMUNE ANNOUNCES CLINICAL RESPONSES ACROSS FIVE SOLID
TUMOR
INDICATIONS WITH AN OVERALL RESPONSE RATE OF 36% AND PROMISING
EARLY DURABILITY FROM ITS NEXT-GENERATION SURPASS TRIAL
    * ADAPTIMMUNE THERAPEUTICS PLC - MAJORITY OF PATIENTS
EXPERIENCED
ANTITUMOR ACTIVITY WITH A DISEASE CONTROL RATE OF 86%
    * ADAPTIMMUNE THERAPEUTICS PLC - ADP-A2M4CD8 CELL THERAPY
SHOWS
IMPROVED TUMOR CELL KILLING AND ENGAGEMENT OF BROADER IMMUNE
SYSTEM TO FIGHT CANCER

Source text for Eikon:  ID:nGNX9DY0mY 
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))